dalcetrapib

Dalcetrapib (INN, development code JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights into the development program, dalcetrapib is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome (ACS) and deliver superior cardiovascular outcome in a specific genetic subset of patients. A companion diagnostic test, developed

Research

266 papers

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib.Clinical pharmacokinetics · 2018
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome.European heart journal · 2022
Dalcetrapib: a review of Phase II data.Expert opinion on investigational drugs · 2010
Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.Journal of lipid research · 2023
Effects of dalcetrapib in patients with a recent acute coronary syndrome.The New England journal of medicine · 2012

via PubMed

Wikidata facts

Mass: 389.239

Show 3 more facts

chemical formula: C₂₃H₃₅NO₂S
canonical SMILES: CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
Commons category: Dalcetrapib

Sources (2)

via Wikidata · CC0

~4 min read

Article

2 sections

Contents

See also
References

{{Chembox | ImageFile = Dalcetrapib.svg | ImageSize = | IUPACName = S-[2-({[1-(2-Ethylbutyl)cyclohexyl]carbonyl}amino)phenyl]-2-methylpropanethioate | OtherNames =

| Section1 =